Medlive Technology Co., Ltd. (HK:2192)
:2192
Want to see HK:2192 full AI Analyst Report?
2192 Stock Chart & Stats
HK$9.83
-HK$0.01(-0.11%)
At close: 4:00 PM EST
HK$9.83
-HK$0.01(-0.11%)
Day’s Range― - ―
52-Week RangeHK$7.51 - HK$17.18
Previous CloseN/A
Volume1.04M
Average Volume (3M)1.46M
Market Cap
HK$6.41B
Enterprise ValueHK$3.03B
Total Cash (Recent Filing)HK$3.72B
Total Debt (Recent Filing)HK$10.11M
Price to Earnings (P/E)19.6
Beta1.31
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.72%
Share Statistics
EPS (TTM)0.27
Shares Outstanding739,958,740
10 Day Avg. Volume901,132
30 Day Avg. Volume1,461,578
Financial Highlights & Ratios
PEG Ratio8.43
Price to Book (P/B)1.31
Price to Sales (P/S)10.21
P/FCF Ratio52.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.10Price Target Upside33.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.48
Revenue Forecast (FY)HK$753.56M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet (minimal Debt)Very low leverage materially reduces financial risk and gives Medlive durable flexibility to fund operations, invest in product development, or pursue strategic M&A without creditor pressure. This conservative capital structure supports resilience across cycles and underpins partner confidence.
Very High Gross And Net MarginsSustained high gross and net margins indicate strong pricing power and low incremental costs in Medlive's digital healthcare services. A durable margin profile bolsters earnings retention, funds reinvestment, and provides a buffer against revenue volatility, supporting long-term cash generation.
Platform Business With Recurring Pharma ClientsA platform model monetizing a physician network with repeat pharmaceutical and healthcare clients creates durable, recurring revenue streams. Scale benefits, targeted data-driven promotion, and long-term client relationships form a structural advantage that enhances predictability and margin leverage over time.
Bears Say
Material Revenue Decline In 2025 (-24%)A 24% top-line contraction represents a significant, lasting risk: it interrupts growth momentum, erodes operating leverage, and may signal client loss or market-share pressure. Sustained revenue weakness would limit reinvestment capacity and force reliance on cost cuts or strategic pivots to restore growth.
Weaker Cash Conversion And Choppy Free Cash FlowEarnings that do not reliably convert into cash reduce financial flexibility. Mixed operating cash conversion and volatile free cash flow constrain funding for growth, dividends, or M&A and increase sensitivity to working-capital swings and client payment timing, raising execution risk over months.
Moderate Returns On Equity (~6–7%)ROE in the mid-single digits suggests limited efficiency in converting equity into shareholder returns, especially with minimal leverage. Persistently moderate ROE constrains long-term upside unless management meaningfully improves margins, asset turnover, or achieves higher sustainable growth.
Medlive Technology Co., Ltd. News
2192 FAQ
What was Medlive Technology Co., Ltd.’s price range in the past 12 months?
Medlive Technology Co., Ltd. lowest stock price was HK$7.51 and its highest was HK$17.18 in the past 12 months.
What is Medlive Technology Co., Ltd.’s market cap?
Medlive Technology Co., Ltd.’s market cap is HK$6.41B.
When is Medlive Technology Co., Ltd.’s upcoming earnings report date?
Medlive Technology Co., Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 124 days.
How were Medlive Technology Co., Ltd.’s earnings last quarter?
Medlive Technology Co., Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.267 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.267.
Is Medlive Technology Co., Ltd. overvalued?
According to Wall Street analysts Medlive Technology Co., Ltd.’s price is currently Undervalued.
Does Medlive Technology Co., Ltd. pay dividends?
Medlive Technology Co., Ltd. pays a Quarterly dividend of HK$0.128 which represents an annual dividend yield of 2.72%. See more information on Medlive Technology Co., Ltd. dividends here
What is Medlive Technology Co., Ltd.’s EPS estimate?
Medlive Technology Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medlive Technology Co., Ltd. have?
Medlive Technology Co., Ltd. has 739,958,740 shares outstanding.
What happened to Medlive Technology Co., Ltd.’s price movement after its last earnings report?
Medlive Technology Co., Ltd. reported an EPS of HK$0.267 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.648%.
Which hedge fund is a major shareholder of Medlive Technology Co., Ltd.?
Currently, no hedge funds are holding shares in HK:2192
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medlive Technology Co., Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$13.10 (33.27% Upside)
HK$13.10 (33.27% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.05%
12-Months-Change
Fundamentals
Return on Equity
6.83%
Trailing 12-Months
Asset Growth
5.66%
Trailing 12-Months
Company Description
Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, which includes project management, clinical monitoring, clinical data management, biostatistics, protocol design, medical monitoring, patient recruitment, and supporting system, as well as digital market research, electronic data capture, real-world studies, and application software development services. The company's medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians, other registered users, such as other healthcare professionals and pharmaceutical companies. Its intelligent patient management solution provides chronic disease management services, comprising online patient consultation, prescription services, and patient management through Internet hospital; and condition-specific patient education services, which includes content development, application software development, and other related services. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in 2021. Medlive Technology Co., Ltd. was founded in 1996 and is headquartered in Beijing, China.
2192 Stock 12 Month Forecast
Average Price Target
HK$13.10
▲(33.27% Upside)
Technical Analysis
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
ClouDr Group Limited
―
IVD Medical Holding Limited
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---